Shield image concept

ActivePure, an infection prevention technology company that provides continuous, whole-department disinfection technology, announced the publication of their study on Methicillin-Resistant Staphylococcus aureus (MRSA), surface microbial burden and Healthcare-Associated Infections (HAIs).

Healthcare-Onset MRSA (HO-MRSA) bacteremia infections had a statistically significant 100 percent decrease (and in fact were eliminated during the trial period) when compared to the same time frame a year prior and the immediate six months prior. This self-operating solution was implemented department-wide in the ICU, and no changes were made or required to the hospital’s cleaning and disinfection practices, trainings or schedules. The study also concluded that the technology in a Medical-Surgical Intensive Care Unit (ICU) resulted in a statistically significant 98 percent reduction of the levels of MRSA surface burden from baseline to final post-activation test.

The study is now available via the Open Forum Infectious Diseases a publication of the Infectious Diseases Society of America (IDSA), and can be found here.

“Keeping patients and team members safe is the top priority for infection prevention and control, and as HAIs in healthcare continue to rise and occur” says Lori Berthelot, RN, BSN, CIC, study co-author and supervisor of infection control at the study hospital.

System Director of Infection Prevention and Control for the study hospital and Study Co-author, Beth Ann Lambert, MS, CIC, added, “It is such an honor to be able to share our experience and encourage others that you can improve the environment of care even during these challenging times of a pandemic and labor shortage crisis.”

The primary author of the study is Caitlin Stowe, MPH, CPC, CIC, CPHQ, VA-BC and vice president of clinical affairs and medical liaison of ActivePure Medical. Additional co-authors of the abstract include Katherine Baumgarten, MD and Nattie Leger, MSN, RN, LSSBB.

"The last few years have exposed the risks of infection by spotlighting the issues that already existed, raising their visibility, but also the 21st century solutions that are now available. The results of this study have opened the door for healthcare facilities to protect their areas prone to the spread of healthcare-associated infections, like MRSA, with proven, real-world results," says Deborah Birx, M.D., chief medical and science advisor of ActivePure Technologies. "ActivePure Medical has worked diligently to prove the efficacy of the technology through extensive testing and FDA clearance. All this work has shown that it is an essential solution for today to address aerosol pathogens like SAR-CoV-2 to multidrug-resistant bacteria and fungi."

To read the complete study, click here.